Neuropathic pain is one of the worst human disorders and affects millions of people worldwide. It can be characterised in headaches and full body sweats. Cannabinoids have been shown to be able to treat this neuropathic pain through their neuroprotective and anti inflammatory properties. Cannabinoids are situated naturally in the marijuana plant (cannabis sativa).
Cannabinoids include tetrahydrocannabinol (THC) and cannabinol (CBD). THC is the psychoactive constituent of marijuana and gives you the stoned feeling when smoked. CBD is the medicinal constituent of marijuana and this allows you the feeling of being relaxed. The endocannabinoid network bares two cannabinoid receptors, 1 and 2, that allow cannabinoids to bind and work throughout the body.
Here is the full scientific article if you wish to download it.
This paper will look at how cannabinoids can be beneficial in assiting the treatment of chronic neuropathic pain.
Cannabinoid receptor 2 agonists have of late garnished concentration as possible therapeutic sites in the regulation of neuropathic pain. In this research, scientists described the pharmacological face of a novel chemical, a cannabinoid receptor 2 agonist. Researchers here showed that radioligand mixing solutions and various functional solutions at human and rodent cannabinoid receptors 1 and 2. MDA19 is a cannabinoid receptor agonist.
The impacts of MDA19 in switching up neuropathic pain were tested in numerous neuropathic pain experiments in rats and in mice. MDA19 displayed 4-fold-greater effectiveness at the human cannabinoid 2 receptor than at the human cannabinoid 1 receptor and nearly 70-fold-greater effectiveness at the rat cannabinoid 2 receptor than at the rat cannabinoid 2 receptor.
In guanosine triphosphate solutions, MDA19 behaved as an agonist at the human cannabinoid 1 and 2 receptors and at the rat cannabinoid 1 receptor but as an inverse agonist at the rat cannabinoid 2 receptor. MDA19 has plausibility for reducing neuropathic pain without producing side impacts in the central nervous system.
Overall, we have produced pharmacological descriptions of a novel cannabinoid 2 agonist, MDA19. This research concludes in the idea that MDA19 may have a massive effect in the treatment of neuropathic pain. Researchers have discovered here that MDA19 acts as a cannabinoid 2 receptor protean agonist and shows a number of functional abilities, relying on the functional solution as well as the various reactions at the human and rodent cannabinoid 2 receptors.
Therefore, useful treatments could be overseen if cannabinoid 2 receptor selective cannabinoids that act as inverse agonists are not assessed. MDA19 was efficient in treating allodynia in rat and mice designs of neuropathic pain by triggering cannabinoid receptors 1 and 2, but did not impact the brain activity of the animals at the active administrative concentration. MDA19 thus has possibility for reducing neuropathic pain without producing adverse effects in the central nervous system.